Category News

Agostinho Carvalho Co-Authors Study on How Low Albumin Increases Risk of Deadly “Black Fungus”

ICVS researcher Agostinho Carvalho is co-author of a study recently published in Nature that explains why some people are more likely to develop mucormycosis, a rare and often deadly fungal infection also known as “black fungus.” This infection gained global attention following its surge in India during the second wave of COVID-19.

Read MoreAgostinho Carvalho Co-Authors Study on How Low Albumin Increases Risk of Deadly “Black Fungus”

ICVS develops a new therapeutic mechanism for Machado–Joseph disease

Researchers from ICVS, in collaboration with i3S, University of Coimbra and international partners, have unveiled a promising new strategy for the treatment of Machado–Joseph disease, also known as Spinocerebellar Ataxia Type 3 (SCA3). The study, published in the prestigious journal Advanced Science, focuses on preventing the aggregation of mutant ataxin-3 protein, the molecular cause of this rare, inherited neurodegenerative disease, for which there is currently no cure.

Read MoreICVS develops a new therapeutic mechanism for Machado–Joseph disease

ICVS Researcher Bruno Costa Contributes to International Project Aiming to Redefine Glioblastoma Treatment

Until now, glioblastoma has been considered the most lethal brain cancer in adults. After two decades, there is no substantial change in survival rates. Classic treatment modalities involving surgery, radiotherapy, and chemotherapy have often shown limited benefits, mainly due to the tumor's underlying resistance mechanisms or due to the inefficacy of drug delivery to the brain itself. In this context, a new research project funded by the la Caixa Foundation is aimed at rethinking the treatment for this disease. Among the partners of this project is ICVS researcher Bruno Costa.

Read MoreICVS Researcher Bruno Costa Contributes to International Project Aiming to Redefine Glioblastoma Treatment

ICVS Spin-off IPLEXMED closes landmark technology transfer agreement with UMinho and INL

A spin-off born at the ICVS has just taken a significant step toward translating biomedical innovation into reality. IPLEXMED signed a major technology transfer agreement with the University of Minho and the INL, acquiring exclusive rights to groundbreaking graphene-based biosensing technology for the detection of malaria and other pathogenic bacteria.

Read MoreICVS Spin-off IPLEXMED closes landmark technology transfer agreement with UMinho and INL

ICVS Researchers Help Uncover How a Natural Brain Molecule May Restore Memory in Alzheimer’s Disease

A new international study, with contribution by a team from the Life and Health Sciences Research Institute at the School of Medicine of the University of Minho has found how increasing the levels of a natural brain molecule, known as NAD⁺, can restore memory in animal models of Alzheimer's disease.

Read MoreICVS Researchers Help Uncover How a Natural Brain Molecule May Restore Memory in Alzheimer’s Disease

Dalila Costa’s Nature Reviews article proposes new concept for explaining cirrhosis progression

ICVS researcher Dalila Costa authored a review in Nature Reviews, "Interaction of inflammation and portal hypertension in cirrhosis progression" proposing a new concept for explaining the mechanisms of decompensated cirrhosis, a serious, but still uncurable disease that affects thousands of people worldwide.

Read MoreDalila Costa’s Nature Reviews article proposes new concept for explaining cirrhosis progression